GlassScriptPhysician profile
Michael A Zell
NPI 1760860704
$63,712.52
in general payments reported to CMS, 2019-2025
27 companies · $23K in 2025
The $23K reported for 2025 was more than what 97% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $779 · 2020: $193 · 2021: $17K · 2022: $156 · 2023: $1,144 · 2024: $21K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $36K · Travel and Lodging: $6,628 · Food and Beverage: $3,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $36,037.50 |
| Travel and Lodging | $6,627.65 |
| Food and Beverage | $3,140.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $59,724.83 | 2021-2025 | 1788, Spy-Phi System, 1688 |
| Boston Scientific Corporation | $1,768.37 | 2019-2025 | Lithovue, Lumenis Pulse 120h, Ams 700 |
| Coloplast Corp | $418.73 | 2019-2025 | Titan |
| Partner Therapeutics, INC. | $337.50 | 2023 | Leukine |
| Procept Biorobotics Corporation | $251.62 | 2020-2024 | Aquabeam System |
| Axonics, INC. | $163.86 | 2023-2024 | Axonics |
| Travere Therapeutics, INC. | $109.08 | 2019 | |
| Urogen Pharma, INC. | $103.85 | 2021 | |
| Astellas Pharma US INC | $99.26 | 2021-2023 | Veozah, Myrbetriq |
| Dentsply Ih Ab | $87.15 | 2023-2024 | Lofric, Lofric |
| Tolmar, INC. | $80.57 | 2023-2025 | Eligard, Jatenzo |
| Abbvie INC. | $73.84 | 2023 | Botox |
| Lumenis, INC | $72.81 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $70.87 | 2021 | |
| Antares Pharma, INC. | $59.87 | 2022-2025 | Xyosted, Nocdurna, Tlando |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $49.26 | 2020 | |
| Photocure INC | $34.48 | 2024 | Cysview |
| Olympus America INC. | $29.22 | 2023-2025 | Itind System |
| Convatec INC. | $27.80 | 2021-2025 | |
| Allergan, INC. | $24.84 | 2021 | |
| Teleflex LLC | $20.13 | 2021 | |
| Palette Life Sciences, INC. | $19.81 | 2022 | |
| Progenics Pharmaceuticals, INC. | $19.42 | 2023 | Pylarify |
| Janssen Biotech, INC. | $18.22 | 2024 | Erleada |
| Calyxo, INC. | $16.92 | 2025 | Cvac Aspiration System |
| Endo Pharmaceuticals INC. | $15.24 | 2021 | |
| Halozyme INC | $14.97 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Zell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.